ATOSSA THERAPEUTICS, INC. (ATOS): Entry into a Material Definitive Agreement
ATOSSA THERAPEUTICS, INC. (ATOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 atos-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026, between Atossa Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on
How this was made
The 30-second read
Why it matters
A new securities purchase agreement typically precedes closing of an equity/warrant issuance; this can change dilution expectations, balance-sheet runway, and near-term trading dynamics.
Market read
Company-specific financing disclosure; traders may reprice dilution and runway expectations ahead of deal closing once full terms are reviewed.
What to watch
Traders should verify the actual purchase price, share/warrant quantities, any investor lock-ups, and whether proceeds fund specific clinical milestones—those details drive whether the market treats it as supportive or dilutive.
Background
The article is an SEC EDGAR 8-K entry into a material definitive agreement, with Exhibit 10.1 containing the securities purchase agreement.
Ticker impact
Atossa Therapeutics filed an 8-K disclosing entry into a material definitive securities purchase agreement (Exhibit 10.1).
Likely modest-to-material downside risk from dilution/financing overhang, with magnitude depending on deal size and terms not shown in the excerpt.
This is a primary SEC 8-K event tied to a securities purchase agreement; however, the provided text excerpt does not include key economic terms (pricing, size, warrants coverage), limiting precision on impact.
Market effects
Adds to the broader biotech financing backdrop where capital raises can reset dilution expectations across small-cap drug developers.
Primarily impacts US small-cap biotech risk appetite and financing-liquidity sentiment.
Limited direct global spillover; mostly company-specific capital structure effects.
Counterpoint
If the financing terms are non-dilutive/strategically structured (e.g., favorable pricing, limited warrant coverage), the market may interpret it as strengthening runway rather than dilution.
Key entities
- issuerAtossa Therapeutics, Inc.
Company entering a material definitive securities purchase agreement disclosed via SEC 8-K (Exhibit 10.1).
